Latest period
−$15.07M
YoY change
-11.5%
5Y CAGR
—
Peak year (2012)
−$7.57K
Latest annual
−$45.79M
Operating Cash Flow history chart for Relmada Therapeutics (RLMD) from 2012 to 2025
Latest: −$45.79M
Operating Cash Flow growth chart for Relmada Therapeutics (RLMD) from 2012 to 2025
Latest: -11.5%
Operating Cash Flow history table for Relmada Therapeutics (RLMD) from 2012 to 2025
| 2025 | −$45.79M | -11.5% | +$5.97M | ||
| 2024 | −$51.76M | +0.2% | −$96.59K | ||
| 2023 | −$51.66M | -50.2% | +$52.14M | ||
| 2022 | −$103.80M | +13.0% | −$11.93M | ||
| 2021 | −$91.87M | +230.4% | −$64.06M | ||
| 2020 | −$27.81M | +229876.9% | −$27.80M | ||
| 2019 | −$12.09K | -99.9% | +$10.49M | ||
| 2018 | −$10.50M | +74.9% | −$4.50M | ||
| 2017 | −$6.00M | -7.2% | +$464.26K | ||
| 2016 | −$6.47M | -50.8% | +$6.68M | ||
| 2015 | −$13.14M | -19.0% | +$3.08M | ||
| 2014 | −$16.23M | +136730.5% | −$16.21M | ||
| 2013 | −$11.86K | +56.8% | −$4.29K | ||
| 2012 | −$7.57K | — | — |
- 2025−$45.79M-11.5%
- 2024−$51.76M+0.2%
- 2023−$51.66M-50.2%
- 2022−$103.80M+13.0%
- 2021−$91.87M+230.4%
- 2020−$27.81M+229876.9%
- 2019−$12.09K-99.9%
- 2018−$10.50M+74.9%
- 2017−$6.00M-7.2%
- 2016−$6.47M-50.8%
- 2015−$13.14M-19.0%
- 2014−$16.23M+136730.5%
- 2013−$11.86K+56.8%
- 2012−$7.57K—
Operating Cash Flow values are taken from Relmada Therapeutics's reported cash flow statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Operating Cash Flow at Relmada Therapeutics (RLMD)
Operating Cash Flow for Relmada Therapeutics (RLMD): headline value −$15.07M · YoY -11.5%. Annual and quarterly series, chart, and tables are below.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
Relmada Therapeutics (RLMD) most recent annual operating cash flow stands at −$45.79M (2025) – declined 11.5% year-over-year.
Across the available history, operating cash flow reached its high of −$7.57K in 2012 and its low of −$103.80M in 2022.
Relmada Therapeutics Operating Cash Flow by Year
Relmada Therapeutics Operating Cash Flow 2025: −$45.79M
Relmada Therapeutics posted operating cash flow of −$45.79M in 2025, declined 11.5% below 2024.
Relmada Therapeutics Operating Cash Flow 2024: −$51.76M
In 2024, Relmada Therapeutics reported operating cash flow of −$51.76M, edged up 0.2% from 2023.
Relmada Therapeutics Operating Cash Flow 2023: −$51.66M
Relmada Therapeutics operating cash flow in 2023 was −$51.66M, plunged 50.2% below 2022.
Relmada Therapeutics Operating Cash Flow 2022: −$103.80M
2022's operating cash flow for Relmada Therapeutics came in at −$103.80M, grew 13.0% from 2021. This figure represents the lowest annual value in the available history.
Relmada Therapeutics Operating Cash Flow 2021: −$91.87M
Relmada Therapeutics operating cash flow in 2021 was −$91.87M.
See more financial history for Relmada Therapeutics (RLMD).
Sector peers by Operating Cash Flow
Healthcare peers of Relmada Therapeutics (RLMD), ranked by their latest operating cash flow
| $24.53B | |
| $19.70B | |
| $19.03B | |
| $18.56B | |
| $16.81B | |
| $16.47B | |
| $14.57B | |
| $9.96B |
- $24.53B
- $19.70B
- $19.03B
- $18.56B
- $16.81B
- $16.47B
- $14.57B
- $9.96B
Frequently asked questions
Relmada Therapeutics (RLMD) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation